Assessing QT prolongation and electrocardiography restitution using a beat-to-beat method by Fossa, Anthony A. & Zhou, Meijian
REVIEW ARTICLE
Cardiology Journal
2010, Vol. 17, No. 3, pp. 230–243
Copyright © 2010 Via Medica
ISSN 1897–5593
230 www.cardiologyjournal.org
Address for correspondence:  Anthony A. Fossa, PhD, iCardiac Technologies, Inc., 150 Allens Creek Road, Rochester,
NY 14618, USA, tel: 585 295 7610, ext. 117, fax: 585 295 7609, e-mail: anthony.fossa@icardiac.com
Assessing QT prolongation and electrocardiography
restitution using a beat-to-beat method
Anthony A. Fossa, Meijian Zhou
iCardiac Technologies, Rochester, New York, USA
Abstract
Historically, the heart rate corrected QT (QTc) interval has been the standard method to assess
for impaired ventricular repolarization, particularly for drug development. However, QTc does
not reflect changes in autonomic state or QT-RR hysteresis which can also affect the interpre-
tation of arrhythmogenic risk. With the advent of more accurate algorithms to automatically
measure the QT interval from continuously collected digital ECG data, usage of heart rate
corrected functions is no longer necessary. The dynamic beat-to-beat QT interval method
compares the QT interval to individual cardiac cycles from all normal autonomic states at
similar RR intervals, thus eliminating the need for correction functions. The upper 97.5%
reference boundary of these beat-to-beat QT interval values is defined across the entire 24-hour
RR interval range. Beats with QT intervals exceeding this limit are flagged as outlier beats for
further arrhythmia vulnerability assessment. The same beat-to-beat technique can also be used
to assess the QT-TQ interval relationship known as ECG restitution. This analysis potentially
provides an additional means to quantify cardiac stress or arrhythmia vulnerability as the
heart works more in relationship to each rest cycle. (Cardiol J 2010; 17, 3: 230–243)
Key words: QT prolongation, autonomic tone, restitution, electrocardiogram,
beat-to-beat
Introduction
The QT interval varies with heart rate and
mathematical formulas have been used since 1920
to normalize the interpretation of the QT interval
[1, 2]. Bazett [1] described how the QT interval di-
vided by the square root of the RR interval (in se-
conds) produced a constant value for QT, which he
termed K. This K eventually was the basis for the
correction term QTc, but even Bazett recognized
that the QT interval/heart rate relationship is more
complex. In his original paper he also described how
K lessened with sympathetic, and increased with
vagal, stimulation and different K values should be
used for varying autonomic states such as standing,
sitting or lying. Since then, more than 20 correc-
tion formulas have been proposed, but none have
been demonstrated to be universally applicable [3].
The importance of proper assessment of the
QT interval was emphasized in the 1990s after the
withdrawal of several marketed drugs that were
found to increase the incidence of sudden cardiac
death related to the polymorphic ventricular tachy-
cardia, torsades de pointes (TdP). Drugs such as
terfenadine [4, 5] and cisapride [6] were shown to
prolong the QT interval which later resulted in re-
gulatory guidance for conduct of clinical studies from
the International Conference of Harmonization
known as ICH E14 [7]. The guidance outlines
a highly-controlled methodology for examination of
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the QTc interval in drug development, known as the
thorough QT/QTc study (TQT), that is designed to
statistically detect an increase of at least 5 ms. With
more TQT studies having been conducted, it is be-
coming evident that some drugs with very low inci-
dences of reported arrhythmia can cause a positive
signal (i.e. a false positive) [8–11]. More important-
ly, there is a risk that dangerous drugs may be inad-
vertently approved because of differing results ob-
tained with QTc methodologies when changes in
heart rate or autonomic state occur (i.e. a false neg-
ative). Both these issues have had a significant im-
pact on the ability of pharmaceutical companies to
bring new medications quickly to the marketplace.
The Food and Drug Administration has recognized
the problem with assessment of QT effects of drugs
that also changes heart rate or autonomic tone and
has initiated an effort with the Cardiovascular Safe-
ty Research Consortium [12] to suggest alternative
methods.
The dynamic beat-to-beat method
One of the alternative methods under consid-
eration is dynamic QT beat-to-beat (QTbtb) analy-
sis. This has been reported to differentiate chang-
es of QT interval duration due to heart rate or au-
tonomic state from impaired repolarization [13].
QTbtb analysis compares QT intervals to individu-
al cardiac cycles from all normal autonomic states
at similar RR intervals, thereby eliminating poten-
tial sources of error from the use of correction func-
tions. All sequential usable beats from continuous-
ly collected electrocardiography (ECGs) are used.
The final dataset boundaries assume all normal hys-
teresis (defined as the lag in QT interval adaptation
for changes in RR interval), sinus arrhythmia and
QT-RR variability are included within the 24-hour
dataset resulting from changes in autonomic state
incurred during activities such as eating, sleeping
and walking. Beats beyond the individual QT re-
ference limit would be assumed to possess poten-
tial risk of arrhythmia for which further analyses
would be necessary (these are described later). The
upper confidence boundary of all beat-to-beat QT
interval values is defined across the entire 24-hour
RR interval range. Beats exceeding this limit are
flagged as outlier beats for further arrhythmia vul-
nerability assessment.
The normal physiological boundary of the QT-RR
relationship is defined from all beats acquired dur-
ing a continuous 24-hour ECG recording under
unstressed conditions of up to 24-hour duration.
The upper (or lower if needed) reference bound can
be defined from the beat-to-beat QT and immedi-
ately preceding RR interval dataset and plotted as
a ‘cloud’ to designate the limit (solid black line in
Fig. 1A). For normal healthy volunteers, we have
used the upper 97.5% reference bound of QT inter-
vals because the heterogeneity increases dramati-
cally beyond this level. When viewing the plots, one
should bear in mind that many of the roughly
100,000 data points (from a 24-hour recording) over-
lap. Therefore the true density distribution of QT-RR
pairs is not immediately evident in a two-dimen-
sional plot. This is apparent in the distribution he-
terogeneity of the 2.5% of plotted beats values that
exist beyond these upper QT interval boundaries.
The boundaries for RR interval are more well-de-
fined. So in order to maximize the range for which
QT assessment can occur, we have found that 99%
of all RR intervals can be included in the analysis.
Since automated algorithms for reading each cardi-
ac cycle can be affected by artifacts, rigorous crite-
ria are also employed for beat flagging of the dataset.
All flagged beats are over-read by analysts to de-
termine if they are usable.
Using the described 24-hour data as a baseline
for all subsequent analyses, the effect of a drug,
placebo and baseline-adjusted placebo-corrected
value can be readily assessed. For any specific time
point or timeframe, e.g. during the peak concentra-
tion of a drug and its time-matched placebo, all beats
are analyzed. Figure 1B shows the five-minute
cloud after dosing of placebo at the Cmax time-
matched period depicted on top of the 24-hour back-
ground QT/RR cloud. The center of this 5-min cloud
of data, or ‘centroid’, is calculated as the median QT
and the median RR interval. This median QT value
(QTbtb) for any nominal time point is compared to
the centroid of all beats extracted within a similar
RR interval range (e.g. ± 12 ms depicted as a rect-
angular slice) from the 24-hour baseline dataset to
provide a delta-QTbtb value (Figure 1D–F). The
beats used to calculate the delta-QTbtb for the no-
minal time points can also be used for calculating
the corrected QTcB or QTcF values (Fig. 2B, C).
The same procedure used to define the delta-QT-
-btb value for the placebo can then be applied for
the on-drug treatment nominal time points (Fig. 2C).
The placebo-adjusted time-matched values (delta-
delta QTbtb) are simply calculated by subtraction
of the time-matched placebo values from the same
time-matched values on treatment from the same
subject (Fig. 2C). For a typical drug study, these
are usually five minute periods taken immediately
before a pharmacokinetic (PK) determination so
that standard delta-delta QTbtb/PK curves can be
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generated (not shown). However, one advantage of
using continuous ECG collection with beat-to-beat
analyses is that entire timeframes of data when on-
drug can be compared to off-drug periods to quick-
ly determine whether an effect is present (Fig. 2D).
This can be further quantified as described below.
An essential component of the beat-to-beat
method is to determine whether repolarization is
significantly impaired beyond normal autonomic
boundaries by applying quantile regression tech-
niques [14] to define the upper 97.5% reference
boundary of QT over RR intervals from the normal
24-hour data (from baseline day of the study). Fi-
gure 2B–D illustrates how the beats during the no-
minal time period on-drug compare against this
baseline relationship. An outlier analysis examines
the percentage of beats that exceed the upper 97.5%
reference boundary of the baseline data during any
period. By definition, for a drug with no effect, this
percentage should be around 2.5% of beats exceed-
ing the upper boundary. The percentage outlier
values can be handled as described above for
QTbtb values, and thus a time-matched placebo-ad-
justed value can be obtained for each time point.
A lower 90% two-sided confidence interval can be
determined for the mean of the percentage outlier
values at any time point to determine whether there
is a statistically significant increase in outliers.
Figure 1. The beat-to-beat analysis process. A. For a single individual, the baseline for comparisons utilizes all QT
and RR intervals collected from continuous ECG recordings over a 24-hour unstressed ambulatory period (   dots).
From the dataset, the 97.5% upper reference bound is defined and plotted in relationship to the 24-hour data
(irregular horizontal line). The baseline consists of all beats within 99% two-sided reference bounds of all RR intervals
(vertical lines); B. Nominal time point values, i.e. from Cmax time-matched period, are collected. This is typically five
minutes of sequential beats extracted from continuous ECG; C. Centroid of nominal time point is calculated by
determining median QT and median RR interval values; D. All beats from 24-hour baseline cloud are extracted that
have similar RR intervals (± 12 ms) compared to nominal time point centroid (represented by vertical rectangular area);
E. Median QT determined from extracted beats of comparator 24-hour centroid data; F. Median centroid QT values
of nominal time point and 24-hour baseline are compared to provide DQTbeat-to-beat (DQTbtb) for placebo baseline.
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Figure 2. Comparison of QTbeat-to-beat (QTbtb) vs QTcB and QTcF values for the same beats during time-matched
placebo and treatment periods in comparison to 24-hour normal boundary from a single subject QT-RR interval
relationship; A. Baseline 24-hour dataset with upper 97.5% QT interval and 99% two-sided RR interval reference
bounds (irregular horizontal line); B. Placebo time-matched nominal time period as calculated in Figure 2 for DQTbtb
compared to same beats where Bazett and Fridericia corrections were used; C. Treatment (DQTbtb, DQTcB, DQTcF)
and placebo-adjusted (DDQTbtb, DDQTcB, DDQTcF) time-matched nominal time period calculated. Note that treat-
ment period produces significant outlier beats above the upper 97.5% QT reference bound, yet QTcB and QTcF
indicate no adverse effect; D. Same technique can be used for entire timeframe that subject is exposed to drug, to
determine whether effect is present.
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As mentioned above, this type of analysis can also
be conducted for any period of time that the drug is
used, including the entire time at efficacious con-
centrations to ascertain the net effect of drug ver-
sus normal QT/RR relationship (Fig. 2D).
One of the strengths of beat-to-beat analysis is
the ability to assess changes in QT interval in vary-
ing autonomic states where QTc can cause false posi-
tive/negative indications of arrhythmia liability [15].
Figure 3 illustrates this concept and is demonstrat-
ed in Figure 4 after reflex tachycardia in a single
individual induced during standing from a supine
position (unpublished study data). When resting
quietly in the supine position (Fig. 4A), the QT and
RR intervals are increased with respect to the
24-hour baseline and the relationship is very flat,
with reduced QT and increased RR variabilities.
When the subject is asked to quickly stand up from
this position, vagal influences lessen and sympa-
thetic influences increase so the QT shortens and
becomes more variable while the RR interval short-
ens during heart rate acceleration. This behavior
creates a short-term hysteresis that deviates from
the baseline correction fit and results in significant
QTcB and QTcF prolongation of greater than 10 ms
during heart rate acceleration (Fig. 4B). The QTbtb
is less affected by the hysteresis and is only slight-
ly prolonged. Almost all beats stay below the up-
per 97.5% reference bound (i.e. less than 2.5% out-
liers). These effects of altered autonomic state on
QT-RR or QTbtb are within normal ranges for the
individual and therefore very different from effects
discussed below where prolonged repolarization of
the QT interval is beyond the normal 24-hour




When a significant increase in the number of
outlier beats is observed, two subsequent analyses
can be performed on the beat-to-beat dataset to
determine the likelihood of increased arrhythmia
vulnerability. The first procedure assesses the hete-
rogeneity of just the outlier beats exceeding the
upper 97.5% reference bounds for QT intervals.
A second procedure performed on all the data, not
just outliers, called ECG restitution, describes the
stability of the beat-to-beat QT interval in relation
to the amount of rest obtained during each cardiac
cycle (TQ interval). ECG restitution also quantifies
the extreme beats that represent increased cardi-
ac stress (described in detail below).
The first procedure to describe heterogeneity
uses a bootstrap analysis [16] and is applied to only
beats that exceed the upper 97.5% reference bound.
The median value during any time period on-drug is
determined, so as to ascertain whether these beats
are of greater magnitude in general compared to
beats normally exceeding the upper 97.5% reference
bound of QT intervals off-drug. Bootstrapping pro-
vides confidence intervals of the median value. The
width of the confidence intervals is used as a mea-
sure of heterogeneity of the QT interval outlier beats,
which has been associated with increased arrhyth-
mia liability [17–19] and can be compared to the width
of the confidence intervals at normal levels from the
same individual when obtained off-drug.
The second procedure is to evaluate the cardi-
ac ECG restitution. Restitution is the ability of the
heart to recover from one beat to the next [20, 21].
This measures the QT interval (working phase of
the heart) in relation to the previous TQ interval
(resting phase of the heart). When the heart is not
under stress, this ratio is less than 1, meaning the
heart is resting more than it is working [22–24].
However, as stress increases on the heart, for ex-
ample during exercise, the heart works more than
it rests, increasing this ratio to greater than 1. An
illustrated example is provided in Figure 6 as well
as by data presented in discussion (Tables 1, 2).
Sustained periods with inadequate recovery be-
tween beats would presumably lead to increased ar-
rhythmia vulnerability, as occurs in extreme cases
with salvos of non-sustained ventricular tachycar-
dia or an R on T phenomenon [25, 26] where TQ
interval equals zero. Arrhythmia liability not asso-
ciated with QT prolongation may be more related
to the TQ interval shortening or increase in the
QT/TQ ratio of each beat. When QT prolongation
is present along with increased QT and RR variabi-
lity or increased heart rate during proarrhythmic
states, the QT/TQ ratio can increase dramatically
for transient periods of time, possibly leading to
initiation of re-entry [21]. Thus, in addition to the
median QT interval, the median TQ interval and
median QT/TQ ratio are assessed in ECG restitu-
tion. To quantify effects on the entire restitution
relationship across all heart rates, several parame-
ters have been developed:
— Lower 5% of TQ intervals: It has been pro-
posed that as the relative refractory period ap-
proaches zero, arrhythmia vulnerability may in-
crease due to the likelihood of re-entry [27].
TQ interval is the ECG equivalent to the dia-
stolic interval, and thus measuring the lower
limit for 95% of the beats was utilized.
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Figure 4. Effect of standing from supine position on QTcB, QTcF and QTbtb to normal 20-hour ambulatory QT-RR
interval relationship. Panels A and B represent effect on beat-to-beat relationship from single subject with results for
entire study (n = 6 normal male volunteers). Note that even though standing response does not produce beats outside
normal range, QTcF and QTcB may reflect impaired repolarization beyond ICH-E14 safety standard.
Figure 3. The normal dynamic QT-RR interval relationship (dotted-line forming asymmetric cloud) encompasses
autonomic reflex responses such as tachycardia (RT) and bradycardia (RB) with hysteresis. The statistical outer
boundary of the normal cloud is defined as the upper 95% confidence bounds. The Fridericia correction factor
applied to the resting QT-RR interval relationship overcorrects dynamic responses in the normal range (striped area
above correction line and below 95% confidence bounds i.e. false positive) or underestimates QT prolongation at
slow heart rates (shaded area above 95% confidence bounds but below Fridericia correction i.e. false negative). QT
prolongation of undefined arrhythmogenic risk (dark shaded area) occurs when exceeding the 95% confidence
bounds of QT intervals during unstressed autonomic influence. From: Fossa et al. J Pharmacol Exp Ther, 2005; 312: 1–11.
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Figure 5. Beat-to-beat QT, RR and TQ interval relationships from a single healthy male subject; A. Relationship of
baseline 24-hour (   diamonds), time-matched i.e. no drug given, baseline response at the Cmax period (   circles;
hours 10am–noon), and nocturnal (  squares; hours 3am–5am) sequential beats showing the QT vs RR intervals,
QT vs TQ intervals and QT/TQ interval ratio vs RR interval; B. Sequential beats occurring during Cmax (   circles) after
160 mg of sotalol; C. 320 mg of sotalol compared to the baseline 22.5-hour and Cmax time-matched responses with
no drug. From: Fossa et al. ANE, 2007; 12: 338–348.
— Percentage of beats with QT/TQ ratio gre-
ater than 1: As the ventricle spends more
time working (QT interval or action potential
duration) per cycle of rest (TQ or diastolic in-
terval), cardiac instability may ensue, theore-
tically leading to increased arrhythmia vulne-
rability. This relationship has been associated
with transition of ventricular tachycardia to
fibrillation by the steepness of the restitution
relationship [23, 28]. Assessment of the
QT/TQ slope from normal sinus rhythm data
would not take into account the density of be-
ats occurring at any one point, and would be
further complicated by hysteresis at a particular
heart rate. Therefore, the percentage of beats
with a QT/TQ ratio greater than 1 reflects the
relative time spent on the restitution curve
where stability is not as certain.
— Upper 98% quantile of the QT/TQ ratio:
This measure reflects the magnitude of the ste-
epness of the restitution relationship. The 98%
quantile takes into account the most extreme
beats with the highest likelihood of leading to
arrhythmia.
A demonstration of this methodology was re-
ported in healthy volunteers following oral doses
of either 160 or 320 mg of sotalol, the IKr and beta-
adrenergic blocker [21] Even though sotalol pro-
duced a dose-dependent increase in the QT inter-
val between 71 and 194 ms, the number of beats
with a QT/TQ ratio greater than 1 was reduced by
25% over the entire day on drug (Fig. 5). This can
be explained by the fact that heart rate slowed in
these individuals due to normal beta-receptor func-
tion blockade with sotalol, thereby allowing the TQ
interval increase to more than offset the increase
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Table 1. Baseline ECG and restitution values.
Parameter Mean baseline values from Holter (SD)
Resting awake Nocturnal 20 h — unstressed
(7–9am)  (3–5am) ambulatory
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
Traditional
Median QT 415 (16) 406 (19) 416 (28) 415 (21) 383 (16) 380 (15)
Median RR 1100 (135) 1058 (144) 1072 (155) 1058 (125) 912 (84) 909 (87)
Median HR 55 (7) 58 (8) 57 (8) 57 (7) 66 (6) 67 (6)
Median QTcB 397 (21) 396 (21) 401 (24) 405 (17) 404 (19) 402 (20)
Median QTcF 403 (16) 399 (16) 406 (21) 408 (15) 397 (16) 395 (17)
Reference regions
Area of discordance 54 (10) 45 (18) 40 (19) 45 (18) See Fig. 8 See Fig. 8
Area of 95% region 22404 21244 31729 23759 41387 40445
(6283)  (4025)  (11803) (11472) (9511) (12261)
Restitution
Median QT 685 (126) 653 (132) 660 (133) 644 (110) 531 (76) 531 (80)
Lower 5% TQ 440 (82) 421 (77) 420 (83) 447 (38) 327 (38) 308 (30)
Median QT/TQ ratio 0.62 (0.11) 0.64 (0.12) 0.64 (0.11) 0.66 (0.10) 0.73 (0.10) 0.73 (0.12)
% QT/TQ ratio > 1 4.36 (4.27) 5.19 (5.41) 4.47 (3.04) 2.75 (1.51) 11.92 (9.79) 12.98 (12.53)
Upper 98% QT/TQ 1.09 (0.20) 1.13 (0.20) 1.18 (0.17) 1.05 (0.08) 1.28 (0.14) 1.34 (0.16)
Figure 6. Relationship between heart rate (RR interval), QT interval and diastolic period (TQ interval) during rest and
tachycardia in the presence and absence of QT prolongation. Please note that this is a hand-drawn illustration for
conceptual purposes and does not accurately reflect interval measurements; Top left complex: Normal resting heart
rate of 60 bpm provides a TQ interval of 570 ms; Top right complex: Tachycardia of 150 bpm reduces TQ interval
approximately seven-fold to 80 ms; Bottom left complex: QT prolongation of 70 ms at resting heart rate of 60 bpm
has relatively little effect on TQ interval (from 570 ms to 500 ms); Bottom right complex: QT prolongation of 70 ms is
combined with tachycardia of 150 bpm to cause dramatic decrease of TQ interval to 10 ms (57-fold reduction from
rest) thus providing little time for oxygenation and return of ion kinetics to normal state for next beat. From: Fossa et
al. J Pharmacol Exp Ther, 2006; 316: 498–506.
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Table 2. ECG and restitution responses after autonomic challenges on two separate days.
Parameter Mean Holter biomarkers from automatic challenges (SD)
Standing Burst exercise                                              Isoproterenol   Phenylephrine
 Acceleration Deceleration
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
Traditional
Median QT 380 (20) 379 (15) 307 (29) 302 (32) 355 (16) 365 (35) 351 (10) 339 (21) 396 (11) 387 (10)
Median RR 801 (141) 742 (127) 466 (76) 440 (49) 565 (39) 584 (53) 609 (69) 556 (32) 1044 (67) 1005 (124)
Median HR 77 (16) 83 (16) 131 (19) 138 (15) 107 (8) 103 (9) 100 (11) 108 (6) 58 (4) 61 (8)
Median QTcB 430 (28) 442 (26) 450 (24) 452 (28) 471 (19) 478 (49) 454 (25) 455 (30) 389 (18) 388 (25)
Median QTcF 413 (16) 421 (11) 397 (23) 395 (28) 428 (17) 435 (42) 417 (17) 413 (25) 392 (15) 387 (17)
Reference regions
% of beats as outliers 27 (38) 16 (23) 83 (23) 84 (12) 74 (14) 62 (31) 52 (32) 66 (23) 22 (9) 16 (8)
Area of 95% ellipse 13878 15754 27733 22122 11228 12633 8018 7611 22002 12583
(5698)  (7500) (31305)  (9868)  (6236)  (8238)  (2850)  (3185)  (17369)  (5480)
Restitution
Median TQ 420 (128) 363 (117) 158 (54) 142 (33) 210 (32) 218 (66) 256 (66) 216 (39) 648 (67) 617 (121)
Lower 5% TQ 238 (42) 240 (54) 134 (48) 101 (35) 162 (24) 147 (45) 162 (33) 155 (33) 460 (89) 446 (57)
Median QT/TQ ratio 1.01 (0.41) 1.17 (0.49) 2.07 (0.49) 2.20 (0.52) 1.73 (0.32) 1.85 (0.72) 1.46 (0.40) 1.62 (0.39) 0.62 (0.08) 0.65 (0.16)
% QT/TQ ratio > 1 44.00 (26.98) 60.67 (26.55) 94.33 (6.62) 93.00 (2.10) 93.95 (11.82) 92.21 (13.74) 86.73 (16.92) 95.77 (4.35) 2.42 (4.74) 6.83 (15.77)
Upper 98% QT/TQ 1.88 (0.42) 1.73 (0.38) 2.77 (0.92) 3.74 (1.52) 2.37 (0.45) 2.90 (1.20) 2.31 (0.43) 2.43 (0.69) 0.94 (0.26) 0.91 (0.18)
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in QT prolongation for each heart beat, thus stabi-
lizing restitution. This may explain how drugs with
significant prolongation can still be used safely in
some therapeutic populations. However, when ECG
restitution was examined in a patient with heart
disease given sotalol, heart rate did not decrease.
Presumably, this was because of a lack of normal
beta-receptor blockade that resulted in a dramatic
increase in the QT/TQ ratio to the point where se-
veral R on T beats were observed before the onset
of TdP (Fig. 7). In this particular case, 98% of all
beats had a QT/TQ ratio greater than 1 even at rest
hours before the onset of arrhythmia.
Discussion
QTc has long been recognized to be a poor
surrogate for assessing arrhythmia liability of drugs
and clinical prognoses. Because of the lack of a bet-
ter surrogate, regulatory emphasis focused on the
precision of the QTc measurement. Since these
studies can be very large due to the number of sub-
jects needed for the statistical design, cost savings
over manual measures were sought. This acceler-
ated the improvements in automated algorithms for
QT measurement [29]. Many of these new automat-
ed algorithms have focused on morphological chang-
es in the multi-lead ECG signal, most importantly
to quantify changes related to spatial heterogeneities
of the heart [30, 31]. With the use of precise auto-
mated ECG interval measures from larger volumes
of data, greater utilization of this software can now
be applied to new continuous ECG methodologies
that allow beat-to-beat analyses and perhaps further
improvements in arrhythmia liability assessment.
The QTbtb methodology was originally devel-
oped to detect subtle cardiovascular effects in drug
discovery using trained conscious dogs with low
resting heart rates. In that model it has undergone
extensive validation with drugs that cause arrhyth-
Figure 7. Restitution prior to torsades de pointes. ECG prior to torsades de points (TdP) event from a 66 year-old
female subject with coronary artery disease given sotalol (2 mg/kg iv over 20 min) and beat-to-beat QT, RR and TQ
interval relationships; A. 10 s of ECG beats prior to TdP showing mix of sinus (    green filled diamonds) and ventricular
(   filled triangles) beats. Relationship of time-matched response to Cmax (   filled circles; hours 10am–noon), and
105 minute period prior to TdP event (  black hollow triangles; hours noon–1:45pm) showing the B: QT vs RR
intervals; C. QT vs TQ intervals and D. QT/TQ interval ratio vs RR interval; Additionally, the last 10 s of beats from
ECG (A) are shown prior to TdP with the arrow pointing to the last sinus beat. From: Fossa et al. ANE, 2007; 12: 338–348.
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mia in man [32, 33]. Since dogs have a more pro-
found sinus arrhythmia than humans, few correc-
tion factors work well across a large heart rate
range, particularly if RR interval measures are av-
eraged at baseline [34]. Hysteresis, or lag in adap-
tation of the QT interval for a given change in RR
interval, plays such an important role in the normal
physiological relationship of the QT-RR intervals,
particularly during sinus arrhythmia [35, 36]. In
humans, this same hysteresis is an important fac-
tor for assessing the QT interval during changes in
heart rate [37] or physiologically induced changes
in hemodynamics or central control of autonomic
tone with or without disease state conditions. Hys-
teresis of the QT interval during heart rate accel-
erations has been shown to increase in patients with
long QT syndromes, and thus may be important in
assessing arrhythmia liability [15, 38, 39]. Howev-
er, correcting for hysteresis or utilizing QTc may
prove difficult to quantify relative to arrhythmia
effects because hysteresis is not constant [35] and
may depend on the degree of heart rate accelera-
tion and the absolute heart rate from which it ac-
celerates. To speculate, this may be why TdP is
associated with a long pause, possibly leading to




In order to fully utilize quantified measures of
beat-to-beat and ECG restitution analyses, the
range of normality in healthy physiological condi-
tions needs to be defined. In studies where these
methods have been used so far, control or placebo
treatment groups have served the purpose of as-
sessing comparative changes. However, if this
method is to be used in patients with pre-existing
conditions, studies related to known clinical out-
comes are necessary to understand the importance
of absolute values. The QT-RR interval functiona-
lity has been reported to be quite reproducible within
the same individual but highly variable between
subjects [40]. This is consistent with findings from
the unpublished data where reference regions of
normality for continuous 24-hour QT-RR data from
six healthy volunteers were shown to have approx-
imately 3% discordance from day to day in the same
individuals (Fig. 8). Larger studies to confirm these
results and quantify similar reference regions in
specific disease states are now needed.
Lastly, since autonomic changes do not always
result in benign outcomes [41–43], normal limits
must be defined for robust perturbations of the beat-
to-beat dynamics that may be encountered in ev-
eryday life but do not result in arrhythmia. This also
will help define the limits for changes observed in
patients at risk for arrhythmia. Tables 1 and 2, ex-
tracted from the above-mentioned study of reference
regions defining normality, show the quantified beat-
to-beat ECG restitution at rest and during four dif-
ferent autonomic challenges, respectively. For
a representative individual (Fig. 9), the QT/TQ re-
lationship across the range of RR intervals is ex-
tremely well defined. As heart rate increases, the
TQ interval diminishes rapidly resulting in a very
robust increase in the QT/TQ ratio beyond 1, with
limits that can be quantified with different autono-
mic challenges. These preliminary data in combina-
tion with other results reported [21] indicate that
healthy individuals have approximately no more
than 20–25% of their cardiac cycles with QT/TQ
ratios greater than 1, with an upper 98% bounds of
approximately 1.3. It is interesting that even though
phenylephrine-induced reflex bradycardia reduced
the upper limits of the QT/TQ ratio, the median
QT/TQ value was increased by approximately 4%
from supine rest, suggesting that hypertension may
have measurable effects on the ECG. Excessive
stress, even in normal healthy individuals with burst
exercise, can increase these limits temporarily by
300–400%. This obviously would be unsustainable.
Further studies from patients experiencing arrhyth-
mia could provide information as to what level or
extent can trigger an arrhythmogenic outcome.
In summary, the strength of beat-to-beat ana-
lysis is that it uses all raw QT-RR interval data,
therefore incorporating QT hysteresis, beat-to-beat
temporal variability and sinus arrhythmia within the
overall upper (or lower if needed) reference bound
for all cardiac cycles. This not only avoids the com-
plexities and inaccuracies of QT correction algo-
rithms, but also allows comparisons under more ex-
treme autonomic changes because no data averag-
ing of the ECG signal or of the QT measurements
is used. This same data can also be used for ECG
restitution analyses to potentially quantify the ar-
rhythmogenic vulnerability due to temporal irre-
gularities.
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